These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 19120397)

  • 41. [Megalotrichiasis and poliosis caused by cyclosporin A].
    Asensio V; del Pozo LJ; Asensio M; Lérida MT
    Med Clin (Barc); 1991 Jun; 97(1):39. PubMed ID: 1857148
    [No Abstract]   [Full Text] [Related]  

  • 42. Topical prostaglandin F(2alpha) analog induced poliosis.
    Chen CS; Wells J; Craig JE
    Am J Ophthalmol; 2004 May; 137(5):965-6. PubMed ID: 15126178
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [A case of recurrent colon cancer with angina pectoris and interstitial pneumonia during cetuximab therapy with death by carcinomatous lymphangiosis].
    Shibahara H; Kuze S; Kyokane T; Takamizawa J; Nakamura H; Morikawa S; Hayashi E; Kinoshita M; Baba S
    Gan To Kagaku Ryoho; 2010 Nov; 37(11):2193-8. PubMed ID: 21084826
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complications of therapy and a diagnostic dilemma case. Case 2. Cutaneous toxicity induced by cetuximab.
    Monti M; Mancini LL; Ferrari B; Rahal D; Santoro A
    J Clin Oncol; 2003 Dec; 21(24):4651-3. PubMed ID: 14673056
    [No Abstract]   [Full Text] [Related]  

  • 45. A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost.
    Chiba T; Kashiwagi K; Ishijima K; Furuichi M; Kogure S; Abe K; Chiba N; Tsukahara S
    Jpn J Ophthalmol; 2004; 48(2):141-7. PubMed ID: 15060793
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Abnormal hair growth in a patient with head and neck cancer treated with the anti-epidermal growth factor receptor monoclonal antibody cetuximab.
    Montagut C; Grau JJ; Grimalt R; Codony J; Ferrando J; Albanell J
    J Clin Oncol; 2005 Aug; 23(22):5273-5. PubMed ID: 16051981
    [No Abstract]   [Full Text] [Related]  

  • 47. Accrual delayed in adjuvant bevacizumab trial.
    Tuma RS
    J Natl Cancer Inst; 2006 Apr; 98(7):439-40. PubMed ID: 16595779
    [No Abstract]   [Full Text] [Related]  

  • 48. Cetuximab-induced hypertrichosis of the scalp and eyelashes.
    Vano-Galvan S; Ríos-Buceta L; Ma DL; Fernández-Chacón C; Viera JC; Jaén P
    J Am Acad Dermatol; 2010 Mar; 62(3):531-3. PubMed ID: 20159332
    [No Abstract]   [Full Text] [Related]  

  • 49. Re-treatment with cetuximab in patients with severe hypersensitivity reactions to cetuximab. Two case reports.
    Nielsen DL; Pfeiffer P; Jensen BV
    Acta Oncol; 2006; 45(8):1137-8. PubMed ID: 17118853
    [No Abstract]   [Full Text] [Related]  

  • 50. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients.
    Hertlein L; Lenhard M; Kirschenhofer A; Kahlert S; Mayr D; Burges A; Friese K
    Arch Gynecol Obstet; 2011 Jan; 283(1):109-13. PubMed ID: 20180130
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Eyelash trichomegaly: report of a case following diffuse hair loss associated with transient malnutrition.
    Honma M; Shimamura T; Komatsu S; Minami-Hori M; Hinooka R; Iizuka H
    J Dermatol; 2013 Sep; 40(9):759-60. PubMed ID: 23834658
    [No Abstract]   [Full Text] [Related]  

  • 52. Two cases of acneiform eruption induced by inhibitor of epidermal growth factor receptor.
    Gencoglan G; Ceylan C
    Skin Pharmacol Physiol; 2007; 20(5):260-2. PubMed ID: 17641540
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Eyelash trichomegaly: review of congenital, acquired, and drug-associated etiologies for elongation of the eyelashes.
    Paul LJ; Cohen PR; Kurzrock R
    Int J Dermatol; 2012 Jun; 51(6):631-46; quiz 643-4, 646. PubMed ID: 22607279
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II trial of mitoxantrone in advanced colorectal cancer.
    Bonnem EM; Mitchell EP; Woolley PV; Smith FP; Neefe J; Smith L; Schein PS
    Cancer Treat Rep; 1982 Nov; 66(11):1995-6. PubMed ID: 7139642
    [No Abstract]   [Full Text] [Related]  

  • 55. Phase II study of N-methylformamide in patients with advanced colorectal cancer.
    Tchekmedyian NS; Kaplan RS; Eisenberger M; Abrams J; Van Echo D
    Cancer Treat Rep; 1987 May; 71(5):541-2. PubMed ID: 3567980
    [No Abstract]   [Full Text] [Related]  

  • 56. Phase II evaluation of vindesine for patients with advanced colorectal carcinoma.
    Saiers JH; Slavik M; McKinney DR
    Cancer Treat Rep; 1982 Mar; 66(3):583-4. PubMed ID: 7060047
    [No Abstract]   [Full Text] [Related]  

  • 57. Complete sustained regression of extensive psoriasis with cetuximab combination chemotherapy.
    Trivin F; Boucher E; Raoul JL
    Acta Oncol; 2004; 43(6):592-3. PubMed ID: 15370619
    [No Abstract]   [Full Text] [Related]  

  • 58. Management of severe infusion reactions after cetuximab.
    Cerman J; Melichar B; Cermanova M; Solichova D
    Acta Oncol; 2008; 47(8):1609-11. PubMed ID: 18607870
    [No Abstract]   [Full Text] [Related]  

  • 59. Reversible hair depigmentation in a patient treated with imatinib.
    Mariani S; Abruzzese E; Basciani S; Fiore D; Persichetti A; Watanabe M; Spera G; Gnessi L
    Leuk Res; 2011 Jun; 35(6):e64-6. PubMed ID: 21176848
    [No Abstract]   [Full Text] [Related]  

  • 60. Acneiform rash secondary to cetuximab plus head and neck radiotherapy.
    Mydin AR; Armstrong JG
    Radiother Oncol; 2007 Oct; 85(1):171. PubMed ID: 17531339
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.